A multifaceted, quality improvement (QI) intervention at a Denver health system was associated with significantly reduced ophthalmic antibiotic prescribing for pediatric conjunctivitis, researchers reported yesterday in the Journal of the Pediatric Infectious Diseases Society.

The QI intervention at Denver Health and Hospital Authority aimed to reduce ophthalmic antibiotic prescribing for conjunctivitis, which can be caused by viruses and bacteria. Despite recommendations advising no or delayed antibiotics for children with conjunctivitis of unknown cause, roughly 60% to 80% of children with infective conjunctivitis receive antibiotics.

The intervention included the creation of an institutional clinical care pathway, changes to conjunctivitis protocols, electronic health record changes, parent education materials, and education for clinicians, nurses, and public school nurses. To evaluate the effectiveness of the intervention, the researchers analyzed antibiotic use and treatment failure in three periods: Pre-COVID, Pre-Intervention (November 2018 to February 2020); COVID, Pre-Intervention (March 2020 to May 2021); and Post-Intervention (June 2021 to December 2022).

Reduction driven by school-age children

Among 6,960 eligible encounters, ophthalmic antibiotic use was reduced by 18.8% from the Pre-COVID, Pre-Intervention period through Post-Intervention. During the Pre-Intervention period following the onset of COVID, a reduction of 16.1% was observed, driven primarily by reduced prescribing among school-aged children. Implementation of the intervention in June 2021 resulted in an additional 2.7% reduction in antibiotic prescribing, primarily in younger children (ages 6 months to 5 years).

The greatest reduction in ophthalmic antibiotic prescribing occurred for nurse triage encounters, with an 82.1% reduction in prescribing rates (from 92.6% to 10.5%). Treatment failure, defined as seeking additional primary or emergency care and prescription of a new antibiotic, occurred in 1,301 children (18.7%) and was more common among children who received an ophthalmic antibiotic than those that did not (20% vs 17.9%).

The study authors say the modification of conjunctivitis protocols was primarily responsible for the reduction in antibiotic use and suggest that clinicians and health systems should evaluate their current prescribing practices for conjunctivitis.

"There are almost certainly opportunities to improve care for a diagnosis that affects a tremendous number of children," they wrote.

The Global Antibiotic Research & Development Partnership (GARDP) today announced a major step in its efforts to bridge global gaps in access to innovative, critically needed antibiotics.

Under a sublicense agreement with GARDP, India-based Orchid Pharma will manufacture cefiderocol, an antibiotic for difficult-to-treat, gram-negative bacterial infections developed by Japanese drugmaker Shionogi. The agreement will enable Orchid to produce the drug cheaper and make it available in low- and middle-income countries (LMICs), many of which are confronting rising rates of antimicrobial resistance (AMR) with a limited arsenal of antibiotics.

The agreement builds on a partnership between GARDP, Shionogi, and the Clinton Health Initiative (CHAI) announced last year, under which Shionogi agreed to grant GARDP the license for cefiderocol. CHAI will work with Shionogi to transfer technology and convey essential manufacturing information to Orchid and other sublicensees to help reduce manufacturing costs, which will make the drug more affordable—pending local authorization or national regulatory approval—for the 135 LMICs that don't currently have access to it.

"We welcome Orchid to this programme and are confident that together we will continue to make strides toward increasing access to medications for people living in low- and middle-income countries," Takuko Sawada, director and vice chairperson of Shionogi's board, said in a company press release.

Reducing the access gap

Cefiderocol was approved by the US Food and Drug Administration in 2019 and the European Medicines Agency in 2020 and is on the World Health Organization Model List of Essential Medicines. It's considered an important weapon against carbapenem- and multidrug-resistant infections, but to date has only been commercially available in high-income countries.

"Access is one of the least talked about issues in the global AMR crisis," said GARDP executive director Manica Balasegaram, MRCP, MSc. "We can effectively offset the burden of antibiotic resistance by reducing the access gap between high- and lower-income countries so that the right antibiotics are affordable and available for appropriate use."

Access is one of the least talked about issues in the global AMR crisis.

A genomic and epidemiologic analysis of data from the 2022 mpox outbreak estimates that 1.3% of men who have sex with men (MSM) in Portugal were infected. 

Led by researchers from Portugal's national institute of health, the study involved the sequencing of 54.2% of the country's 495 confirmed mpox cases. Viral samples were obtained from May 4 to September 16, 2022.

Among the 447 patients with demographic data, 99.1% were men, 96.5% were MSM, 44.1% were aged 30 to 39 years, 28.4% were aged 20 to 29, and 20.4% were 40 to 49. A total of 42.9% of the patients with HIV information (168 of 392) were HIV-positive.

Sex networks, saunas fed mpox spread

Portugal was one of the first countries to report mpox cases in 2022. An estimated 62% of the country's cases were reported, and 1.3% of MSM were infected. Sexual networks and superspreader gatherings such as at saunas played a critical role in mpox spread.

In April, the R_t (expected number of infections caused by an infected person in a population in which some people might be immune) was 2.25, peaking at 2.70 in May. In total, 182 genetic subclusters were identified globally, with 78.3% including at least two Portuguese sequences, which made up 66.6% of sequences from Portugal. There was a link between travel-related countries and those with a high percentage of sequences in Portuguese subclusters.

Our findings highlight genomic epidemiology as a tool for the real-time monitoring and control of mpox epidemics, and can guide future vaccine policy in a highly susceptible population.

Of the 399 cases with information on probable transmission routes, 95.2% identified sexual contact, 3.3% cited nonsexual contact, and 0.5% reported healthcare-associated spread.

"Our findings highlight genomic epidemiology as a tool for the real-time monitoring and control of mpox epidemics, and can guide future vaccine policy in a highly susceptible population," the study authors wrote.

The global mpox outbreak began in May 2022, with 88,600 confirmed infections and 152 deaths reported in 113 countries across all world regions by August 2, 2023. As of January 10, 2023, 951 mpox cases had been confirmed in Portugal.